Keyphrases
Venous Thromboembolism
100%
Cost Perspective
100%
Low Molecular Weight Heparin
66%
Apixaban
66%
Vitamin K Antagonists
66%
Parenteral Anticoagulants
66%
Rivaroxaban
50%
Cost Analysis
50%
Drug Costs
50%
Healthcare Sector
33%
Oral Anticoagulants
33%
Societal Perspective
33%
Denmark
16%
Daily Clinical Practice
16%
Pulmonary Embolism
16%
Deep Vein Thrombosis
16%
Bleeding
16%
Recurrent Venous Thromboembolism
16%
Healthcare
16%
Economic Cost
16%
Health Care Costs
16%
Health Economic Analysis
16%
Pairwise Comparison
16%
Societal Costs
16%
Therapy Choice
16%
Scarce Resources
16%
Edoxaban
16%
Economic Impact
16%
Dabigatran Etexilate
16%
Non-vitamin K Antagonist Oral Anticoagulants
16%
Economic Perspective
16%
Venous Thromboembolism Treatment
16%
Drug Budget
16%
Nursing and Health Professions
Anticoagulant Agent
100%
Venous Thromboembolism
100%
Low Molecular Weight Heparin
57%
Antivitamin K
57%
Apixaban
57%
Health Care Cost
42%
Cost Benefit Analysis
42%
Drug Cost
42%
Rivaroxaban
42%
Clinical Practice
14%
Bleeding
14%
Health Service
14%
Economic Analysis
14%
Health Economics
14%
Retinol
14%
Deep Vein Thrombosis
14%
Lung Embolism
14%
Vitamin K Group
14%
Dabigatran Etexilate
14%
Edoxaban
14%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
100%
Anticoagulant Agent
100%
Low Molecular Weight Heparin
57%
Apixaban
57%
Antivitamin K
57%
Rivaroxaban
42%
Deep Vein Thrombosis
14%
Lung Embolism
14%
Bleeding
14%
Retinol
14%
Vitamin K Group
14%
Edoxaban
14%
Dabigatran Etexilate
14%
Medicine and Dentistry
Venous Thromboembolism
100%
Health Care Cost
100%
Antithrombotic
46%
Apixaban
26%
Low Molecular Weight Heparin
26%
Vitamin K Antagonist
26%
Rivaroxaban
20%
Cost Benefit Analysis
20%
Health Care
13%
Decision Making
13%
Bleeding
6%
Deep Vein Thrombosis
6%
Pulmonary Embolism
6%
Retinol
6%
Edoxaban
6%
Dabigatran Etexilate
6%